Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027627 (
metastases
)
103,950
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Gain of the long arm of chromosome 8 (8q) is one of the most common gains found in the advanced prostate cancer by comparative genomic hybridization. We have previously identified a putative target gene for the 8q gain,
EIF3S3
, that encodes a p40 subunit of eukaryotic translation initiation factor 3 (eIF3). Here, we studied the frequency of the
EIF3S3
amplification in different stages of prostate cancer and co-amplification of
EIF3S3
and oncogene MYC. In addition, prognostic utility of the
EIF3S3
copy number alteration was evaluated. The analyses were done with fluorescence in situ hybridization and tissue microarray technology. High-level amplification of
EIF3S3
was found in 11 of 125 (9%) of pT1/pT2 tumors, 12 of 44 (27%) of pT3/pT4 tumors, and 8 of 37 (22%) of lymph node
metastases
as well as in 26 of 78 (33%) and 15 of 30 (50%) of hormone refractory locally recurrent tumors and
metastases
, respectively. The amplification was associated with high Gleason score (P < 0.001). One of the 79 tumors with
EIF3S3
amplification had only two copies of MYC, whereas all tumors with amplification of MYC had also amplification of
EIF3S3
indicating common co-amplification of the genes. Gain of
EIF3S3
was associated with poor cancer-specific survival in incidentally found prostate carcinomas (P = 0.023). In the analyses of prostatectomy-treated patients, the amplification was not statistically significantly associated with progression-free time. In conclusion, amplification of
EIF3S3
gene is common in late-stage prostate cancer suggesting that it may be functionally involved in the progression of the disease.
...
PMID:Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. 1173 59